Developing a vaccine to prevent Entamoeba histolytica infections
Official title: Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine
Funded at Access to Advanced Health Institute · NIH-10551100 · Data updated 2026-11-12
This study is working on a new nasal vaccine to help protect people from a parasite that causes serious stomach issues, and if it works well in tests, it could offer a new way to prevent these infections in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Access to Advanced Health Institute NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 21, 2018 |
| Project end | November 22, 2025 |
| Funding year | 2022 |
| Award (this year) | $3,674,481 |
| NIH project number | 272201800025C-P00007-9999-1 |
| Project ID | NIH-10551100 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Entamoeba histolytica infections, particularly those in endemic regions or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for Entamoeba histolytica infections or those who have already been infected may not benefit from this research.
What this research studies
This research focuses on creating a synthetic vaccine that can be administered intranasally to protect against Entamoeba histolytica, a parasite that causes severe intestinal disease. The project involves formulating the vaccine, testing its stability, and evaluating its effectiveness and safety in nonhuman primates before moving to human clinical trials. Patients may benefit from this vaccine if it proves effective, as it could provide a new preventive measure against infections caused by this parasite.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of Entamoeba histolytica infections in humans.
How similar studies have gone: While there have been various vaccine development efforts for other infectious diseases, this specific approach to an Entamoeba histolytica vaccine is relatively novel and has not been extensively tested.
Where this research is happening
-
Access to Advanced Health Institute
Seattle, United States Active
Researchers
- Principal investigator: Fox, Christopher — Access to Advanced Health Institute
- Study coordinator: Fox, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.